Fluvoxamine May Not Improve COVID-19 Outcomes
Fluvoxamine, a drug approved to treat obsessive-compulsive disorder, showed promise in some trials as a potentially inexpensive treatment f…
Fluvoxamine, a drug approved to treat obsessive-compulsive disorder, showed promise in some trials as a potentially inexpensive treatment f…
The changes to 42 CFR Part 2, many of which APA supported, will better align the rule with HIPAA, improve care coordination between health professionals,…
A majority of young adults can correctly identify at least one sign of opioid overdose, but relatively few know how to administer naloxone,…
The drug offers something new for patients—a side-effect profile that does not include sexual or weight gain risks.
Working in psychiatry exposes you to the extremes of the human condition: rage, shame, panic, fear, melancholy, and grief. Part of our role as psychiatrists…
Acculturation, assimilation, discrimination, and social determinants of health all play roles in risk of substance use and access to treatment, experts say.
APA’s next president-elect is a former speaker of the APA Assembly and long-time public sector psychiatrist who has focused on improving access and delivery of…
Terminating a treatment relationship with a patient can be difficult, but following the guidance in this article should mitigate liability risk.
A significant percentage of positions in subspecialty fellowships go unfilled each year, with occupancy rates for addiction, consultation-liaison, forensic, and geriatric psychiatry all averaging l…
Researchers found that restless sleep in midlife was associated with worse cognition more than 10 years later. Duration of sleep, however, was not associated with…
The ebb and flow of societal beliefs often resemble a pendulum’s swing, oscillating between acceptance and rejection. This phenomenon is not confined to the annals…